A Stage-Based Approach to Therapy in Parkinson’s Disease

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side effects, contraindications, as well as dosage and methods of administration, are highlighted here, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.

RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours

“…Despite the many studies on PD over the years, its pathogenesis remains unclear, and treatment remains difficult [91]. Studies have shown that AKT also plays a role in PD signal transduction.…”

The Pharmacology of Visual Hallucinations in Synucleinopathies

“…Alterations of the serotonergic system are a typical finding in synucleinopathies (Seidel et al, 2015;Wilson et al, 2019). Moreover, antipsychotic drugs modulating serotonergic transmission are now widely employed to treat VH, especially in PD and DLB patients (Carrarini et al, 2019). Further investigations will be nevertheless needed to clarify the fine downstream mechanism involved in these processes.…”

Apitherapy for Parkinson’s Disease: A Focus on the Effects of Propolis and Royal Jelly

“…Progressive deterioration of motor functions such as resting tremor, rigidity, and bradykinesia is a key feature of PD, primarily associated with dopaminergic neurodegeneration. The Hoehn and Yahr scale is widely used to assess PD patients according to five disease stages, which range from only unilateral involvement in stage I to being wheelchair- or bed-bound in stage V [ 19 ]. Nonetheless, the clinical picture of the disease varies considerably among patients, even within the same stage.…”

“…Cumulative evidence denotes that degeneration of dopaminergic neurons in the SNC of patients with PD occurs mainly at stage III, along with a concomitant loss of serotonergic neurons in the serotonergic raphe nuclei and cholinergic neurons in the nucleus basalis of Meynert and in the perineuronal nets [ 20 , 21 ]. Thereby, PD entails a significant reduction of serotonergic and cholinergic markers, which is associated with decline of cognitive functions, mood dysregulations, fatigue, insomnia, weight loss, autonomic dysfunction, olfactory abnormalities, and GI dysfunction such as constipation, nausea, bloating, drooling, delayed gastric emptying, and prolonged intestinal transit time [ 10 , 12 , 19 , 21 , 22 ].…”

“…Even more, some of them (e.g., GI symptoms) interfere with the action of the drug and severely alter patients' quality of life [ 6 , 10 ]. Therefore, recent researches have focused on the use of multifunctional, natural agents, and nutritional modifications as safe adjunctive treatments to impede disease progress, alleviate its symptoms, and promote quality of life in PD patients [ 6 , 19 ]. Figure 1 briefly summarizes factors associated with PD and its underlying mechanism.…”